Abstract: The invention provides mechanisms for the co-localization in a living cell of a target molecule and of an inhibitor for the target molecule. The invention also provides novel chimeric tRNALys-ribozyme molecules that compete effectively with tRNALys for HIV-1 reverse transcriptase binding sites. The chimeric human tRNALys-ribozymes inhibit HIV reverse transcription by delivering inhibitors such as ribozymes of HIV-1 reverse transcriptase directly to the virion particle and render it non-functional. The chimeric molecules of the invention thus serve as highly specific non-toxic therapeutic agents and vaccines for viral, including lentiviral, infections. These chimeric molecules also reveal a novel, site specific RNA cleaving activity of HIV-1.

Abstract: Pathogenetic allele variants that predispose to a disease can be identified by stratifying affected sib pairs by allele-sharing statuss at two or more candidate loci. This locus stratification method has been used to identify an allelic variant at the ATM locus which is implicated in breast cancer.

Abstract: Pathogenetic allele variants that predispose to a disease can be identified by stratifying affected sib pairs by allele-sharing statuss at two or more candidate loci. This locus stratification method has been used to identify an allelic variant at the ATM locus which is implicated in breast cancer.

Abstract: The invention provides novel chimeric tRNA.sup.LYS -ribozyme molecules that compete effectively with tRNA.sup.LYS for HIV-1 reverse transcriptase binding sites. The chimeric human tRNA.sup.LYS -ribozymes inhibit reverse HIV transcription by delivering inhibitors such as ribozymes of HIV-1 reverse transcriptase directly to the virion particle and render it non-functional. The chimeric molecules of the invention thus serve as highly specific non-toxic therapeutic agents. These chimeric molecules also reveal a novel, site specific RNA cleaving activity of HIV-1.